The DOI matches its Crossref record.
Effective Doses of Recombinant Human Bone Morphogenetic Protein-2 in Experimental Spinal Fusion
Abstract
STUDY DESIGN: Nineteen dogs underwent L4-L5 intertransverse process fusions with either 58 micrograms, 115 micrograms, 230 micrograms, 460 micrograms, or 920 micrograms of recombinant human bone morphogenetic protein-2 carried by a polylactic acid polymer. A previous study (12 dogs) compared 2300 micrograms of recombinant human bone morphogenetic protein-2, autogenous iliac bone, and carrier alone in this model. All fusions subsequently were compared. OBJECTIVES: To characterize the dose-response relationship of recombinant human bone morphogenetic protein-2 in a spinal fusion model. SUMMARY OF BACKGROUND DATA: Recombinant osteoinductive morphogens, such as recombinant human bone morphogenetic protein-2, are effective in vertebrate diaphyseal defect and spinal fusion models. It is hypothesized that the quality of spinal fusion produced with recombinant human bone morphogenetic protein-2, above a threshold dose, does not change with increasing amounts of inductive protein. METHODS: After decortication of the posterior elements, the designated implants were placed along the intertransverse process space bilaterally. The fusion sites were evaluated after 3 months by computed tomography imaging, high-resolution radiography, manual testing, mechanical testing, and histologic analysis. RESULTS: As in the study using 2300 micrograms of recombinant human bone morphogenetic protein-2, implantation of 58-920 micrograms of recombinant human bone morphogenetic protein-2 successfully resulted in intertransverse process fusion in the dog by 3 months. This had not occurred in animals containing autograft or carrier alone. The cross-sectional area of the fusion mass and mechanical stiffness of the L4-L5 intersegment were not dose-dependent. Histologic findings varied but were not related to rhBMP-2 dose. Inflammatory reaction to the composite implant was proportional inversely to the volume of the fusion mass. CONCLUSIONS: No mechanical, radiographic, or histologic differences in the quality of intertransverse process fusion resulted from a 40-fold variation in dose of recombinant human bone morphogenetic protein-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Boden, S. D., Zdeblick, T. A., Sandhu, H. S., & Heim, S. E. (2000) · Spine · doi:10.1097/00007632-200002010-00020 · Cited by 667
Self-citationBone Morphogenetic Protein and Bone Morphogenetic Protein Gene Family in Bone Formation and Repair
Wozney, J. M., & Rosen, V. (1998) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199801000-00006 · Cited by 611
Review of bone graft and bone substitutes with an emphasis on fracture surgeries
Sohn, H.-S., & Oh, J.-K. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0157-y · Cited by 526
Bone morphogenetic proteins in human bone regeneration
Groeneveld, E., & Burger, E. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420009 · Cited by 404
Bone growth factors in maxillofacial skeletal reconstruction
Schliephake, H. (2002) · International Journal of Oral and Maxillofacial Surgery · doi:10.1054/ijom.2002.0244 · Cited by 390
Metadata
- Authors
- Sandhu, H. S., Kanim, L. E. A., Kabo, J. M., Toth, J. M., Zeegen, E. N., Liu, D., Delamarter, R. B., & Dawson, E. G.
- Venue
- Spine
- Published
- 1996-09
- Volume
- 21
- Issue
- 18
- Pages
- 2115-2122
- ISSN
- 0362-2436 (ISSN-L)
- OpenAlex
- W2329018393
- Cited by
- 211
- References
- 0
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effective Doses of Recombinant Human Bone Morphogenetic Protein-2 in Experimental Spinal Fusion. https://app.cochat.ai/papers/10.1097/00007632-199609150-00012
- The paper
- Sandhu, H. S., Kanim, L. E. A., Kabo, J. M., Toth, J. M., Zeegen, E. N., Liu, D., Delamarter, R. B., & Dawson, E. G. (1996). Effective Doses of Recombinant Human Bone Morphogenetic Protein-2 in Experimental Spinal Fusion. Spine. https://doi.org/10.1097/00007632-199609150-00012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.